Do you change your approach to prednisone taper based on rituximab dosing regimen when treating patients with pemphigus?

My approach to prednisone course/tapering at treatment outset or subsequent rituximab is typically dictated by clinical parameters, specifically PDAI/severity and potential comorbidities, rather than rituximab dosing regimen. This paper supports the notion that similar cumulative steroid exposure an...

If treating with rituximab, I typically will start at a lower dose of prednisone, an amount needed to keep the patient comfortable until the antibodies have cleared. I taper as clinically tolerated.